A possible explanation may be of small sample size; confounding variables that affect prognoses such as age, cancer stage or grade, histology of ovarian cancer or chemotherapy regime, etc. The differences in clinical features of BRCA1/2 mutation carriers and those patients with mutations in genes other than BRCA1/2 remained to be established in larger cohorts. Here, BRCA1 is linked to cancer.